Company: SRPT
Filing Date: 2025-03-03
Form Type: S-3ASR
Source: 0001193125-25-044088
Chunk: 32

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-03-03
Form: S-3ASR
Chunk 32
---
us to the extent that a statement contained in this prospectus or any prospectus supplement modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute a part of this prospectus.

We will provide without charge to each person, including
any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus, other than exhibits to such
documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates. You should direct written requests to: Sarepta Therapeutics, Inc., 215 First Street, Suite 415, Cambridge, MA 02142, or
you may call us at (617) 274-4080.

24

PART II INFORMATION NOT REQUIRED IN PROSPECTUS Item 14. Other Expenses of Issuance and Distribution. The following table sets forth the various costs and expenses (other than the underwriting discounts and commissions) payable by the company in connection with the issuance and registration of securities registered hereby. All amounts are estimates.

| SEC registration fee                             |     | $ | -1 |
| Transfer agent’s and trustee’s fees and expenses |     |   | -2 |
| Printing costs                                   |     |   | -2 |
| Legal fees and expenses                          |     |   | -2 |
| Blue Sky fees and expenses                       |     |   | -2 |
| Accounting fees and expenses                     |     |   | -2 |
| Miscellaneous expenses                           |     |   | -2 |
| Total                                            |     |   | -2 |

| (1) | The registrant is registering an indeterminate amount of securities under this Registration Statement and in                     
 reliance upon Rules 456(b) and 457(r) of the Securities Act, the registrant is deferring payment of all of the registration fee. |

| (2) | These fees are calculated based on the number of issuances and the amount of securities offered and accordingly                                                                    
 cannot be estimated at this time. The applicable prospectus supplement will set forth the estimated aggregate amount of expenses payable in respect of any offering of securities. |

Item 15. Indemnification of Directors and Officers. The registrant is a Delaware corporation. Subsection (b)(7) of Section 102 of the Delaware General Corporation Law (the “DGCL”), enables a